Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹776.20 - ₹1,260.00
Previous CloseN/A
Volume67.81K
Average Volume (3M)11.95K
Market Cap
₹262.84B
Enterprise Value₹259.18B
Total Cash (Recent Filing)₹3.06B
Total Debt (Recent Filing)₹5.64B
Price to Earnings (P/E)74.5
Beta1.08
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.25
Shares Outstanding212,285,660
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,270.00Price Target Upside25.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.54
Revenue Forecast (FY)₹26.60B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin MomentumA >100% annual revenue increase with net margin expansion to ~15.9% indicates durable scaling of higher-value services and improved operating leverage. Sustained top-line growth plus expanding margins support lasting profitability improvements and stronger return generation as programs move from discovery to commercial supply.
Conservative Balance SheetLow and falling leverage provides financial flexibility to invest in capacity, fund development programs, or absorb volatility. A conservative balance sheet reduces refinancing risk, enables selective M&A or capex spending, and supports long-term stability while the company scales its CRDMO footprint.
Integrated CRDMO Model & Customer StickinessAn end-to-end CRDMO offering lets SAI capture multi-stage program economics as molecules progress from discovery to commercial supply. This vertical integration increases switching costs, supports multi-year revenue per program, and enhances cross-sell potential—structural advantages in outsourced pharma services.
Bears Say
Persistent Negative Free Cash FlowSustained negative FCF despite strong accounting profits implies the business is not yet converting earnings into surplus cash. Over the medium term this can constrain self‑funding for capex or working capital, increase reliance on external financing, and reduce resilience to market or customer slowdowns.
Worsening Cash Conversion TrendA ~63.5% YoY decline in free cash flow signals rising capex or working-capital absorption as the company scales. If cash conversion does not stabilize, growth may come at the cost of higher funding needs, pressuring margins and potentially limiting returns on incremental investment.
Gross Margin CompressionA drop in gross margin points to input-cost pressure or pricing stress in core manufacturing services. For a CRDMO, sustained gross-margin pressure reduces headroom for operating-margin expansion and could blunt ROE gains, especially if competitive or raw-material dynamics persist over the medium term.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹776.20 and its highest was ₹1260.00 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹262.84B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on May 14, 2026. The company reported ₹4.9 earnings per share for the quarter, missing the consensus estimate of ₹5.1 by -₹0.2.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,285,660 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹4.9 in its last earnings report, missing expectations of ₹5.1. Following the earnings report the stock price went up 2.42%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,270.00
▲(25.71% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―







